Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company’s IgA nephropathy (IgAN) portfolio
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company’s IgA nephropathy (IgAN) portfolio
arcticnovartis
- In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + supportive care at 36 weeks1